The study looked at data from the Sweden National Diabetes Register to determine what patient characteristics were related to all-cause mortality or death from cardiovascular-, diabetes-, or cancer-related causes.
Intensive treatment was defined as use of more glucose-lowering medications than recommended by practice guidelines and was found in 18.7% of clinically complex Medicare patients.
The U.K.-based retrospective cohort study used a database that linked national hospitalization and mortality data for people who were prescribed second-line regimens after metformin.
Excess mortality associated with diabetes was highest in patients younger than age 75 who had had diabetes for a longer time period, with the relative hazard highest in women, a study found.
A 1-hour glucose value above 155 mg/dL predicted mortality even when the 2-hour glucose value was below 140 mg/dL, according to the 33-year study.
The results of this study pose the question of whether the increased likelihood of bladder cancer, which is rare, justifies withholding pioglitazone from adults with type 2 diabetes, according to an accompanying editorial.
Researchers used data from the ADVANCE-ON study to develop the AD-ON risk score, a 10-year risk score for the combined endpoint of major cardiovascular disease (CVD) or chronic kidney disease.
Incretin-based drugs not associated with greater heart failure hospitalization risk than other drug combos in retrospective study
Researchers compared patients taking dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) analogues to those taking 2 or more oral antidiabetic drugs.
The warnings are based on a review finding 73 cases of ketoacidosis in patients with type 1 or type 2 diabetes and 19 cases of life-threatening urosepsis and pyelonephritis.
The industry-funded, double-blind, randomized, controlled trial assigned adult patients with type 2 diabetes who were not taking antihyperglycemic agents before the study to 26 weeks of treatment in 1 of 5 arms.